Paris, France (May 25, 2026) – EssilorLuxottica presented new clinical data and long-term evidence on Essilor Stellest lenses† at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, alongside findings from independent researchers. Across 12 myopia-focused abstracts, findings from randomized controlled trials, long-term follow-up, real-world clinical practice, combination approaches, and mechanistic research contributed to an integrated evidence ecosystem, supporting more comprehensive and personalized myopia management.

“Integrated evidence in myopia management combines clinical trials, real-world data, and mechanistic understanding to deliver consistent, personalized, and clinically meaningful outcomes across the patient journey,” said Olga Prenat, Head of Medical & Professional Affairs at EssilorLuxottica.

Long-term and clinical evidence

Long-term results from a seven-year follow-up study of Essilor Stellest lenses† (spectacle lenses with highly aspherical lenslets or HAL lenses) in China demonstrated sustained efficacy in children and adolescents. The lenses† slowed myopia progression by 2.30 D and axial elongation by 0.92 mm on average for all subjects over seven years.¹ The outcomes observed in adolescents up to 19 years of age also showed a reduced risk of developing high myopia with Essilor Stellest lens† wear over seven years compared with single vision lenses. These results highlight the importance of continued intervention throughout adolescence.

Results from a prospective, randomized, multicenter clinical trial conducted in the United States among children aged 6 to 12 demonstrated that Essilor Stellest lenses† slowed myopia progression by 71% on average and axial elongation by 53% over two years, compared with single vision lenses^.2

Efficacy was observed across all age groups and baseline myopia levels, with stronger effects seen in younger children.³ The study also demonstrated a favorable safety profile, with stable visual acuity and high compliance and retention over two years.4 Additional analyses indicated no impact on the rate of astigmatism change over two years,⁵ confirming previously reported results in Chinese pediatric populations.^6,7 Essilor Stellest lenses† received U.S. FDA market authorization in September 2025⁸ and are currently the first and only spectacle lenses authorized in the United States for specific pediatric myopia indications.

Convergence of evidence across clinical settings and patient populations

Findings presented further reinforced the integrated evidence base supporting HAL spectacle lenses across clinical trials, real-world clinical practice, and diverse patient populations.

A review of published evidence across 26 studies conducted in multiple patient populations, including 17 in China, showed consistent findings for Essilor Stellest lenses. † Among the 10 studies that included a single vision lens control group, axial elongation in children wearing HAL spectacle lenses was consistently lower than in those wearing single vision lenses, regardless of study design or geographic location.⁹These results highlight the consistent efficacy of Essilor Stellest lenses† across clinical settings and populations.

Real-world evidence presented at ARVO 2026 and later published in Ophthalmology Science¹⁰ showed that different spectacle lens designs slowed myopia progression in clinical practice compared with single vision lenses. HAL spectacle lenses incorporating H.A.L.T.* technology were associated with the largest reduction in axial length in this retrospective cohort study. Additional real-world evidence in children with low myopia further supported HAL lenses as showing the most robust myopia progression control effect across spectacle lens designs.¹¹

Research presented at ARVO 2026 also highlighted the potential benefit of combination approaches to myopia management. An independent study showed that combining HAL spectacle lenses with low-dose atropine maintained strong myopia progression control over 24 months, compared with atropine alone.¹²

A large school-based study in Shanghai demonstrated that integrated interventions, including HAL lens wear and increased outdoor time, may help reduce incident myopia and slow axial elongation in myopic and pre-myopic children.¹³

Together, these findings reflect the continued maturation of myopia management, with converging data across clinical trials, real-world practice and independent research supporting comprehensive and personalized approaches across the myopia care continuum, from delaying onset to slowing progression.

Advancing future approaches in myopia management

ARVO 2026 also highlighted EssilorLuxottica’s continued innovation in understanding myopia development and in potentially predicting how well a myopia progression control lens will slow eye growth. Research presented explored how the retina may use chromatic contrast cues to detect defocus, contributing to a growing understanding of the mechanisms involved in myopia progression.14 A separate study demonstrated that retinal contrast metrics may be used to predict the efficacy of myopia progression control lenses,15 potentially supporting the development and evaluation of future lens designs.

Through continued investment in research and innovation, EssilorLuxottica continues to support eye care professionals across the patient journey while advancing next-generation solutions such as Essilor Stellest 2.0 lenses. ‡

Notes

_{This communication is intended for scientific exchange only and does not constitute medical or therapeutic recommendations.}

_{* H.A.L.T. Highly Aspherical Lenslet Target. H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.}

_{† Essilor Stellest lens regulatory status and product availability may vary by country. U.S. FDA authorization and indications for use are based solely on clinical trial data from the U.S.}

_{‡ Essilor® Stellest® 2.0 lenses are currently not available in all countries, including the United States, and have not been cleared by the FDA in the U.S.}

_{1. Li X, et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 7-year follow-up study. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 0968}

_{2. Shen J, et al. Two‑year safety and effectiveness of Stellest lenses for slowing myopia progression in a US pediatric population. ARVO 2026; 2026 May 3‑7; Denver, CO. Poster 1229-0999}

_{3. Lim EW, et al. Impact of age and baseline myopia on the effectiveness of Stellest lenses in a US pediatric population. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 1196-0966}

_{4. Gelb C, et al. Safety and visual acuity outcomes of Stellest lenses: 2-year results from a US pivotal trial. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 1201-0971}

_{5. Wong YL, et al. Comparison of 24-month astigmatism changes between Stellest and single vision lenses in US children. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 1229-0967}

_{6. Bao J, et al. Two-year changes in cylinder power in myopic children wearing spectacle lenses with highly aspherical lenslets and single vision spectacle lenses. Investigative Ophthalmology & Visual Science. 2024 Jun 17;65(7):160-.9.}

_{7. Wen K, et al. Effect of Three Types of Specially-Designed Myopia Control Spectacle Lenses on Astigmatism: A Two-Year Result. Ophthalmic and Physiological Optics. 2026 Apr 8:1-7. doi: 10.1007/s44402-026-00077-5}

_{8. U.S. FDA. FDA authorizes marketing of first eyeglass lenses to slow progression of pediatric myopia. Sep 2025. https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia}

_{9. Bullimore M, et al. Myopia Control with Spectacle Lenses with Highly Aspherical Lenslets (HAL). ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 0978}

_{10. Ganesh SC, et al. Comparative effectiveness of myopia-control spectacle lenses: Real-world performance from a retrospective cohort study. Ophthalmology Science. 2026 Feb 2:101103.}

_{11. Liu C, et al. Real-world effectiveness of three myopia-control spectacle lens designs in children with low myopia. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1223-0993.}

_{12. Sim B, et al. Efficacy of Combined Highly Aspherical Lenslet Target (HALT) Spectacles and Low-Dose Atropine in Children with Poor Response to Atropine Monotherapy over 24 Months. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 1002;}

_{13. He J, et al. The School-based Myopia Prevention and Control Integrated Study in Shanghai：6-month results. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Presentation 1879}

_{14. Ditullio R, et al. Coloring our perspective: the importance of chromatic features in emmetropization. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 0103}

_{15. Hamlaoui S, et al. Predicting the efficacy of myopia control lenses by simulating their optical effect on the retina. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 4646}

DOWNLOAD THE PRESS RELEASE